The DOI matches its Crossref record; 499 of the 502 references it cites were found in a registry or an index.
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
Open accessAbstract
PREAMBLE The study of NAFLD has intensified significantly, with more than 1400 publications since 2018, when the last American Association for the Study of Liver Diseases (AASLD) Guidance document was published.1 This new AASLD Guidance document reflects many advances in the field pertinent to any practitioner caring for patients with NAFLD and emphasizes advances in noninvasive risk stratification and therapeutics. A separate guideline focused on the management of patients with NAFLD in the context of diabetes has been written jointly by the American Association of Clinical Endocrinology and AASLD.2 Given the significant growth in pediatric NAFLD, it will not be covered here to allow for a more robust discussion of the diagnosis and management of pediatric NAFLD in the upcoming AASLD Pediatric NAFLD Guidance. A “Guidance” differs from a “Guideline” in that it is not bound by the Grading of Recommendations, Assessment Development and Evaluation system. Thus, actionable statements rather than formal recommendations are provided herein. The highest available level of evidence was used to develop these statements, and, where high-level evidence was not available, expert opinion was used to develop guidance statements to inform clinical practice. Key points highlight important concepts relevant to understanding the disease and its management. The most profound advances in NAFLD relevant to clinical practice are in biomarkers and therapeutics. Biomarkers and noninvasive tests (NITs) can be used clinically to either exclude advanced diseases or identify those with a high probability of cirrhosis.3,4 NIT “cut points” vary with the populations studied, underlying disease severity, and clinical setting. Those proposed in this guidance are meant to aid decision-making in the clinic and are not meant to be interpreted in isolation. Identifying patients with “at-risk” NASH (biopsy-proven NASH with stage 2 or higher fibrosis) is a more recent area of interest. Although the definitive diagnosis and staging of NASH remain linked to histology, noninvasive tools can now be used to assess the likelihood of significant fibrosis, predict risk of disease progression and decompensation, make management decisions, and, to some degree, assess response to treatment. There is an ongoing debate over the nomenclature of fatty liver disease, which had not been finalized at the time this guidance was published. At the culmination of a rigorous consensus process, it is intended that any formal change in nomenclature will advance the field without a negative impact on disease awareness, clinical trial endpoints, or the drug development/approval process. Furthermore, it should allow for the emergence of newly recognized disease subtypes to address the impact of disease heterogeneity, including the role of alcohol, on disease progression and response to therapy. Input from patients has been central to all stages of the consensus process to ensure the minimization of nomenclature-related stigma. DEFINITIONS NAFLD is an overarching term that includes all disease grades and stages and refers to a population in which ≥5% of hepatocytes display macrovesicular steatosis in the absence of a readily identified alternative cause of steatosis (eg, medications, starvation, monogenic disorders) in individuals who drink little or no alcohol (defined as < 20 g/d for women and <30 g/d for men). The spectrum of disease includes NAFL, characterized by macrovesicular hepatic steatosis that may be accompanied by mild inflammation, and NASH, which is additionally characterized by the presence of inflammation and cellular injury (ballooning), with or without fibrosis, and finally cirrhosis, which is characterized by bands of fibrous septa leading to the formation of cirrhotic nodules, in which the earlier features of NASH may no longer be fully appreciated on a liver biopsy. UPDATE ON EPIDEMIOLOGY AND NATURAL HISTORY The prevalence of NAFLD and NASH is rising worldwide in parallel with increases in the prevalence of obesity and metabolic comorbid disease (insulin resistance, dyslipidemia, central obesity, and hypertension).5,6 The prevalence of NAFLD in adults is estimated to be 25%–30% in the general population7–9 and varies with the clinical setting, race/ethnicity, and geographic region studied but often remains undiagnosed.10–14 The associated economic burden attributable to NASH is substantial.15–17 The prevalence of NASH in the general population is challenging to determine with certainty; however, NASH was identified in 14% of asymptomatic patients undergoing colon cancer screening.14 This study also highlights that since the publication of a prior prospective prevalence study,18 the prevalence of clinically significant fibrosis (stage 2 or higher fibrosis) has increased >2-fold. This is supported by the projected rise in NAFLD prevalence by 2030, when patients with advanced hepatic fibrosis, defined as bridging fibrosis (F3) or compensated will the proj
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Based on this, it seems reasonable to conclude that should patients continue to complete guideline-based amounts of aerobic exercise over a longer duration, fibrosis improvement may follow [35, 36].”
From Aerobic Exercise Training Leads to MASH Resolution as Defined by the MASH Resolution Index (2026) · cites this paper as [35]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, interventions in diet and physical activity are considered to be the cornerstone of management in the whole MASLD spectrum [7, 10].”
From Effects of Mediterranean diet, exercise, and their combination on body composition and liver outcomes in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of randomized controlled trials (2025) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although there is no consensus on the optimal diet for treating MASLD, the EASL-EASD-EASO guidelines recently recommended the MD as the preferred option [7, 10].”
From Effects of Mediterranean diet, exercise, and their combination on body composition and liver outcomes in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of randomized controlled trials (2025) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Current guidelines recommend weight loss through dietary modifications, increased physical activity, or both combined in MASLD patients [7, 11, 12].”
The cited source says what the claim attributes to it.
In the citing paper
“Various scienti fi c societies have recommended clinical care pathways with an emphasis on the use of non-invasive tests (NITs) and the liaison between primary care/non-hepatology and hepatology settings.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [126]
In the citing paper
“GLP-1RA-based drugs have been proven beneficial to some extent in dedicated trials and should be considered in patients with obesity and/or T2D and metabolic dysfunction-associated steatohepatitis (MASH)90.”
From Incretin-based therapies for the treatment of obesity-related diseases (2024) · cites this paper as [90]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–400 of 499
Nonalcoholic Fatty Liver Disease
Zhao, Y.-C., Zhao, G., Chen, Z., She, Z., Cai, J., & Li, H. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.13419 · Cited by 244
Siddiqui, M. S., Fuchs, M. A., Idowu, M. O., Luketic, V. A., Boyett, S. L., Sargeant, C., Stravitz, R. T., Puri, P., Matherly, S. C., Sterling, R. K., et al. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.10.008 · Cited by 240
Self-citationSex hormones and their receptors regulate liver energy homeostasis
Shen, M., & Shi, H. (2015) · International Journal of Endocrinology · doi:10.1155/2015/294278 · Cited by 239
Chronic liver injury during obstructive sleep apnea†
Tanné, F., Gagnadoux, F., Chazouillères, O., Fleury, B., Wendum, D., Lasnier, E., Lebeau, B., Poupon, R. Y., & Serfaty, L. (2005) · Hepatology · doi:10.1002/hep.20725 · Cited by 238
Couillard, C. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.3.1026 · Cited by 237
Katsuki, A., Sumida, Y., Urakawa, H., Gabazza, E. C., Murashima, S., Maruyama, N., Morioka, K., Nakatani, K., Yano, Y., & Adachi, Y. (2003) · Diabetes Care · doi:10.2337/diacare.26.8.2341 · Cited by 236
An assessment by the Statin Liver Safety Task Force: 2014 update
Bays, H. E., Cohen, D. E., Chalasani, N., & Harrison, S. A. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.02.011 · Cited by 235
Younes, R., & Bugianesi, E. (2019) · Seminars in Liver Disease · doi:10.1055/s-0038-1677517 · Cited by 235
The role of nutrition in non‐alcoholic fatty liver disease: Pathophysiology and management
Berná, G., & Romero‐Gómez, M. (2020) · Liver International · doi:10.1111/liv.14360 · Cited by 235
Sun, F., Wu, S., Wang, J., Guo, S., Chai, S., Yang, Z., Li, L., Zhang, Y., Ji, L., & Zhan, S. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.11.008 · Cited by 232
Farrell, G. C. (2002) · Seminars in Liver Disease · doi:10.1055/s-2002-30106 · Cited by 231
Donati, G., Stagni, B., Piscaglia, F., Venturoli, N., Morselli‐Labate, A. M., Rasciti, L., & Bolondi, L. (2004) · Gut · doi:10.1136/gut.2003.027086 · Cited by 231
Fracanzani, A. L., Petta, S., Lombardi, R., Pisano, G., Russello, M., Consonni, D., Marco, V. D., Cammà, C., Mensi, L., Dongiovanni, P., et al. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.04.045 · Cited by 230
Properzi, C., O'Sullivan, T. A., Sherriff, J. L., Ching, H. L., Jeffrey, G. P., Buckley, R. F., Tibballs, J., MacQuillan, G. C., Garas, G., & Adams, L. A. (2018) · Hepatology · doi:10.1002/hep.30076 · Cited by 227
Impact of coffee on liver diseases: a systematic review
Saab, S., Mallam, D., Cox, G. A., & Tong, M. J. (2013) · Liver International · doi:10.1111/liv.12304 · Cited by 226
Role of Cholesterol‐Associated Steatohepatitis in the Development of NASH
Horn, C. L., Morales, A. L., Savard, C. E., Farrell, G. C., & Ioannou, G. N. (2021) · Hepatology Communications · doi:10.1002/hep4.1801 · Cited by 225
Argo, C. K., Patrie, J. T., Lackner, C., Henry, T. D., de Lange, E. E., Weltman, A. L., Shah, N. L., Al-Osaimi, A. M., Pramoonjago, P., Jayakumar, S., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.08.036 · Cited by 224
Yasutake, K., Nakamuta, M., Shima, Y., Ohyama, A., Masuda, K., Haruta, N., Fujino, T., Aoyagi, Y., Fukuizumi, K., Yoshimoto, T., et al. (2008) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520802588133 · Cited by 222
Loomba, R., Yang, H.-I., Su, J., Brenner, D., Barrett-Connor, E., Iloeje, U., & Chen, C.-J. (2013) · American Journal of Epidemiology · doi:10.1093/aje/kws252 · Cited by 221
Golabi, P., Otgonsuren, M., de Avila, L., Sayiner, M., Rafiq, N., & Younossi, Z. M. (2018) · Medicine · doi:10.1097/md.0000000000010214 · Cited by 221
PNPLA3, CGI‐58, and Inhibition of Hepatic Triglyceride Hydrolysis in Mice
Wang, Y., Kory, N., BasuRay, S., Cohen, J. C., & Hobbs, H. H. (2019) · Hepatology · doi:10.1002/hep.30583 · Cited by 220
Obstructive Sleep Apnea, Insulin Resistance, and Steatohepatitis in Severe Obesity
Polotsky, V. Y., Patil, S. P., Savransky, V., Laffan, A. M., Bevans‐Fonti, S., Frame, L. A., Steele, K., Schweizter, M. A., Clark, J. M., Torbenson, M. S., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200804-608oc · Cited by 218
Non‐invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE
Doycheva, I., Cui, J. Y., Nguyen, P., Costa, E. A., Hooker, J. C., Hofflich, H., Bettencourt, R., Brouha, S. S., Sirlin, C. B., & Loomba, R. S. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13405 · Cited by 216
Self-citationMetabolic and Behavioral Characteristics of Metabolically Obese but Normal-Weight Women
Conus, F., Allison, D. B., Rabasa-Lhoret, R., St-Onge, M., St-Pierre, D. H., Tremblay-Lebeau, A., & Poehlman, E. T. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0265 · Cited by 215
Bazick, J., Donithan, M., Neuschwander‐Tetri, B. A., Kleiner, D. E., Brunt, E. M., Wilson, L., Doo, E., Lavine, J. E., Tonascia, J., & Loomba, R. S. (2015) · Diabetes Care · doi:10.2337/dc14-1239 · Cited by 214
Self-citationEkstedt, M., Franzén, L., Holmqvist, M., Bendtsen, P., Mathiesen, U., Bodemar, G., Ekstedt, M., Franzén, L., Holmqvist, M., Bendtsen, P., et al. (2008) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520802555991 · Cited by 211
Thyroid function and the risk of nonalcoholic fatty liver disease: the Rotterdam study
Bano, A., Chaker, L., Plompen, E. P. C., Hofman, A., Dehghan, A., Franco, O. H., Janssen, H. L. A., Murad, S. D., & Peeters, R. P. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1300 · Cited by 209
Haigh, L., Kirk, C., El Gendy, K., Gallacher, J., Errington, L., Mathers, J. C., & Anstee, Q. M. (2022) · Clinical Nutrition · doi:10.1016/j.clnu.2022.06.037 · Cited by 209
Sato, K., Gosho, M., Yamamoto, T., Kobayashi, Y., Ishii, N., Ohashi, T., Nakade, Y., Ito, K., Fukuzawa, Y., & Yoneda, M. (2014) · Nutrition · doi:10.1016/j.nut.2014.11.018 · Cited by 207
Klair, J. S., Yang, J. D., Abdelmalek, M. F., Guy, C. D., Gill, R. M., Yates, K. P., Ünalp–Arida, A., Lavine, J. E., Clark, J. M., Diehl, A. M., et al. (2016) · Hepatology · doi:10.1002/hep.28514 · Cited by 207
Self-citationMRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis
Noureddin, M., Truong, E., GORNBEIN, J. A., Saouaf, R., Guindi, M. M., Todo, T., Noureddin, N., Yang, J. D., Harrison, S. A., & Alkhouri, N. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.012 · Cited by 207
Kumarendran, B., O’Reilly, M. W., Manolopoulos, K. N., Toulis, K. A., Gokhale, K. M., Sitch, A. J., Wijeyaratne, C. N., Coomarasamy, A., Arlt, W., & Nirantharakumar, K. (2018) · PLOS Medicine · doi:10.1371/journal.pmed.1002542 · Cited by 206
Leveraging Human Genetics to Identify Potential New Treatments for Fatty Liver Disease
Romeo, S., Sanyal, A. J., & Valenti, L. V. C. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.12.002 · Cited by 206
Hoofnagle, J. H., Natta, M. L. V., Kleiner, D. E., Clark, J. M., Kowdley, K. V., Loomba, R. S., Neuschwander‐Tetri, B. A., Sanyal, A. J., & Tonascia, J. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12352 · Cited by 205
Self-citationCusi, K., Bril, F., Barb, D., Polidori, D., Sha, S., Ghosh, A., Farrell, K., Sunny, N. E., Kalavalapalli, S., Pettus, J., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13584 · Cited by 204
Self-citationHarris, R., Harman, D. J., Card, T. R., Aithal, G. P., & Guha, I. N. (2017) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(16)30205-9 · Cited by 203
Targher, G., Valbusa, F., Bonapace, S., Bertolini, L., Zenari, L., Rodella, S., Zoppini, G., Mantovani, W., Barbieri, E., & Byrne, C. D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057183 · Cited by 201
Bruno, S., Maisonneuve, P., Castellana, P., Rotmensz, N., Rossi, S., Maggioni, M., Persico, M., Colombo, A., Monasterolo, F., Casadei-Giunchi, D., et al. (2005) · BMJ · doi:10.1136/bmj.38391.663287.e0 · Cited by 201
NAFLD and Chronic Kidney Disease
Marcuccilli, M. E., & Chonchol, M. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17040562 · Cited by 201
Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease
Hagström, H., Talbäck, M., Andreasson, A., Walldius, G., & Hammar, N. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.06.007 · Cited by 199
Relation of Nonalcoholic Hepatic Steatosis to Early Carotid Atherosclerosis in Healthy Men
Targher, G., Bertolini, L., Padovani, R., Zenari, L., Zoppini, G., & Falezza, G. (2004) · Diabetes Care · doi:10.2337/diacare.27.10.2498 · Cited by 197
Pavlides, M., Banerjee, R., Tunnicliffe, E. M., Kelly, M., Collier, J. D., Wang, L. M., Fleming, K. A., Cobbold, J., Robson, M. D., Neubauer, S., et al. (2016) · Liver International · doi:10.1111/liv.13284 · Cited by 197
Petta, S., Sebastiani, G., Viganò, M., Ampuero, J., Wai-Sun Wong, V., Boursier, J., Berzigotti, A., Bugianesi, E., Fracanzani, A. L., Cammà, C., et al. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.06.045 · Cited by 197
Pharmacotherapy of type 2 diabetes: An update
Upadhyay, J., Pοlyzos, S. A., Perakakis, N., Thakkar, B., Paschou, S. Α., Katsiki, N., UNDERWOOD, P. C., Park, K., Seufert, J., Kang, E. S., et al. (2017) · Metabolism · doi:10.1016/j.metabol.2017.08.010 · Cited by 196
Ciardullo, S., Monti, T., & Perseghin, G. (2020) · Diabetes Care · doi:10.2337/dc20-1778 · Cited by 196
Sharpton, S. R., Schnabl, B., Knight, R., & Loomba, R. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2020.11.010 · Cited by 194
Self-citationTaylor-Weiner, A. N., Pokkalla, H., Han, L., Jia, C., Huss, R. S., Chung, C., Elliott, H. L., Glass, B., Pethia, K., Carrasco‐Zevallos, O. M., et al. (2021) · Hepatology · doi:10.1002/hep.31750 · Cited by 194
Self-citationVilar‐Gomez, E., Vuppalanchi, R., Gawrieh, S., Ghabril, M., Saxena, R., Cummings, O. W., & Chalasani, N. (2020) · Hepatology · doi:10.1002/hep.30368 · Cited by 193
Cusi, K. J., Sanyal, A. J., Zhang, S., Hartman, M. L., Bue‐Valleskey, J. M., Hoogwerf, B. J., & Haupt, A. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12973 · Cited by 193
The role of growth hormone and insulin-like growth factor-I in the liver
Takahashi, Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071447 · Cited by 193
Abdelmalek, M. F., Lazo, M., Horska, A., Bonekamp, S., Lipkin, E. W., Balasubramanyam, A., Bantle, J. P., Johnson, R. J., Diehl, A. M., & Clark, J. M. (2012) · Hepatology · doi:10.1002/hep.25741 · Cited by 190
Self-citationMa, J., Hennein, R., Liu, C., Long, M. T., Hoffmann, U., Jacques, P. F., Lichtenstein, A. H., Hu, F. B., & Levy, D. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.03.038 · Cited by 187
Diet and exercise in NAFLD/NASH: Beyond the obvious
Semmler, G., Datz, C., Reiberger, T., & Trauner, M. (2021) · Liver International · doi:10.1111/liv.15024 · Cited by 187
Loomba, R. S., Wong, R. J., Fraysse, J., Shreay, S., Li, S., Harrison, S. A., & Gordon, S. C. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15679 · Cited by 187
Self-citationBonapace, S., Perseghin, G., Molon, G., Canali, G., Bertolini, L., Zoppini, G., Barbieri, E., & Targher, G. (2011) · Diabetes Care · doi:10.2337/dc11-1820 · Cited by 182
Nishizawa, H., Iguchi, G., Murawaki, A., Fukuoka, H., Hayashi, Y., Kaji, H., Yamamoto, M., Suda, K., Takahashi, M., Seo, Y., et al. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0252 · Cited by 181
Younossi, Z. M., Tampi, R. P., Racila, A., Qiu, Y., Burns, L. C., Younossi, I. M., & Nader, F. (2019) · Diabetes Care · doi:10.2337/dc19-1113 · Cited by 179
Fromenty, B., Fisch, C., Labbe, G., Degott, C., Deschamps, D., Berson, A., Lettéron, P., & Pessayre, D. (1990) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22984-6 · Cited by 178
Risks of light and moderate alcohol use in fatty liver disease: follow-up of population cohorts
Åberg, F., Puukka, P., Salomaa, V., Männistö, S., Lundqvist, A., Valsta, L., Perola, M., Färkkilä, M., & Jula, A. (2020) · Hepatology · doi:10.1002/hep.30864 · Cited by 176
Patel, N. S., Doycheva, I., Peterson, M. R., Hooker, J., Kisselva, T., Schnabl, B., Seki, E., Sirlin, C. B., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.08.039 · Cited by 173
Self-citationRole of non‐alcoholic steatohepatitis in methotrexate‐induced liver injury
Langman, G., Hall, P. D. L. Μ., & Todd, G. (2001) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2001.02644.x · Cited by 172
Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases
Chun, Y. S., Laurent, A., Maru, D. M., & Vauthey, J. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70064-6 · Cited by 171
Histopathologic analysis of suspected amiodarone hepatotoxicity
Lewis, J. H., Mullick, F. G., Ishak, K. G., Ranard, R. C., Ragsdale, B. D., Perse, R. M., Rusnock, E. J., Wolke, A. M., Benjamin, S. B., Seeff, L. B., et al. (1990) · Human Pathology · doi:10.1016/0046-8177(90)90076-h · Cited by 171
Sanyal, A. J., Anstee, Q. M., Trauner, M., Lawitz, E. J., Abdelmalek, M. F., Ding, D., Han, L., Jia, C., Huss, R. S., Chung, C., et al. (2022) · Hepatology · doi:10.1002/hep.32204 · Cited by 171
Self-citationLäutamaki, R., Borra, R., Iozzo, P., Komu, M. E. S., Lehtimäki, T. J., Salmi, M., Jalkanen, S., Airaksinen, J. K. E., Knuuti, J. M., Parkkola, R., et al. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00604.2005 · Cited by 170
Luukkonen, P. K., Qadri, S., Ahlholm, N., Porthan, K., Männistö, V., Sammalkorpi, H., Penttilä, A. K., Hakkarainen, A., Lehtimäki, T. E., Gaggini, M., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.10.013 · Cited by 170
Jaruvongvanich, V., Sanguankeo, A., Riangwiwat, T., & Upala, S. (2017) · Annals of Hepatology · doi:10.5604/01.3001.0009.8593 · Cited by 170
Alcohol Consumption and Alcoholic Liver Disease: Evidence of a Threshold Level of Effects of Ethanol
Savolainen, V. T., Liesto, K. K., Männikkö, A., Penttilä, A., & Karhunen, P. J. (1993) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.1993.tb05673.x · Cited by 168
Anthérieu, S., Rogue, A., Fromenty, B., Guillouzo, A., & Robin, M. (2011) · Hepatology · doi:10.1002/hep.24290 · Cited by 168
Jung, J., Loomba, R., Imajo, K., Madamba, E. V., Gandhi, S., Bettencourt, R., Singh, S., Hernandez, C., Valasek, M. A., Behling, C. A., et al. (2020) · Gut · doi:10.1136/gutjnl-2020-322976 · Cited by 168
Self-citationEliasson, B., Liakopoulos, V., Franzén, S., Näslund, I., Svensson, A.-M., Ottosson, J., & Gudbjörnsdottir, S. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00334-4 · Cited by 167
Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis
Caussy, C., Soni, M., Cui, J. Y., Bettencourt, R., Schork, N. J., Chen, C., Ikhwan, M., Bassirian, S., Cepin, S., Gonzalez, M. P., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci93465 · Cited by 166
Self-citationBae, J. C., Suh, S., Park, S. E., Rhee, E., Park, C., Oh, K. W., Park, S. W., Kim, S. W., Hur, K. Y., Kim, J. H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046819 · Cited by 165
Rinella, M. E., Dufour, J.-F., Anstee, Q. M., Goodman, Z., Younossi, Z., Harrison, S. A., Loomba, R., Sanyal, A. J., Bonacci, M., Trylesinski, A., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.10.029 · Cited by 164
Stanley, T. L., Chen, C. Y., Branch, K. L., Makimura, H., & Grinspoon, S. K. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1587 · Cited by 163
Patel, J. R., Bettencourt, R., Cui, J. Y., Salotti, J., Hooker, J. C., Bhatt, A., Hernandez, C., Nguyen, P., Aryafar, H., Valasek, M. A., et al. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16656735 · Cited by 163
Self-citationPioglitazone and bladder cancer risk: a systematic review and meta‐analysis
Tang, H., Shi, W., Fu, S., Wang, T., Zhai, S., Song, Y., & Han, J. (2018) · Cancer Medicine · doi:10.1002/cam4.1354 · Cited by 162
Paige, J. S., Bernstein, G. S., Heba, E. R., Costa, E. A. C., Ferreira, M. P. F. D., Wolfson, T. J., Gamst, A. C., Valasek, M. A., Lin, G., Han, A., et al. (2017) · American Journal of Roentgenology · doi:10.2214/ajr.16.16726 · Cited by 161
Self-citationCirculating fetuin-A and free fatty acids interact to predict insulin resistance in humans
Stefan, N., & Häring, H.-U. (2013) · Nature Medicine · doi:10.1038/nm.3116 · Cited by 160
Ajmera, V. H., Belt, P. H., Wilson, L., Gill, R. M., Loomba, R. S., Kleiner, D. E., Neuschwander‐Tetri, B. A., & Terrault, N. A. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.01.026 · Cited by 157
Self-citationWijarnpreecha, K., Thongprayoon, C., & Ungprasert, P. (2016) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000776 · Cited by 156
Cui, J. Y., Ang, B., Haufe, W. M., Hernandez, C., Verna, E. C., Sirlin, C. B., & Loomba, R. S. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13196 · Cited by 155
Self-citationKim, S., Kwon, H., Park, J., Cho, B., Kim, D., Oh, S., Lee, C. M., & Choi, H.-C. (2012) · BMC Gastroenterology · doi:10.1186/1471-230x-12-69 · Cited by 155
TM6SF2: A Novel Genetic Player in Nonalcoholic Fatty Liver and Cardiovascular Disease
Luo, F., Oldoni, F., & Das, A. (2021) · Hepatology Communications · doi:10.1002/hep4.1822 · Cited by 155
Visceral adipose tissue area is an independent risk factor for hepatic steatosis
Park, B. J., Kim, Y. J., Kim, D., Kim, W. K., Jung, Y. J., Yoon, J., Kim, C. Y., Cho, Y. M., Kim, S. H., Lee, K. B., et al. (2007) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2007.05212.x · Cited by 154
Effect of exercise on the development of new fatty liver and the resolution of existing fatty liver
Sung, K., Ryu, S., Lee, J., Kim, J., Wild, S. H., & Byrne, C. D. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.026 · Cited by 154
Brunt, E. M., Kleiner, D. E., Wilson, L. A., Sanyal, A. J., Neuschwander‐Tetri, B. A., & for the Nonalcoholic Steatohepatitis Clinical Research Network (2019) · Hepatology · doi:10.1002/hep.30418 · Cited by 154
Mantovani, A., Nascimbeni, F., Lonardo, A., Zoppini, G., Bonora, E., Mantzoros, C. S., & Targher, G. (2018) · Thyroid · doi:10.1089/thy.2018.0257 · Cited by 154
Young, S. K., Tariq, R., Provenza, J., Satapathy, S. K., Faisal, K., Choudhry, A., Friedman, S. L., & Singal, A. K. (2020) · Hepatology Communications · doi:10.1002/hep4.1519 · Cited by 154
NAFLD: Reporting Histologic Findings in Clinical Practice
Brunt, E. M., Kleiner, D. E., Carpenter, D. H., Rinella, M. E., Harrison, S. A., Loomba, R. S., Younossi, Z. M., Neuschwander‐Tetri, B. A., & Sanyal, A. J. (2020) · Hepatology · doi:10.1002/hep.31599 · Cited by 153
Self-citationKäräjämäki, A. J., Pätsi, O.-P., Savolainen, M. J., Kesäniemi, Y. A., Huikuri, H. V., & Ukkola, O. H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142937 · Cited by 152
Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial
JOY, T. R., McKenzie, C. A., Tirona, R. G., Summers, K. L., Seney, S. L., Chakrabarti, S., Malhotra, N., & Beaton, M. D. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i1.141 · Cited by 152
Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes
Lomonaco, R., Bril, F., Portillo-Sánchez, P., Ortiz‐Lopez, C., Orsak, B., Biernacki, D., Lo, M. C., Suman, A., Weber, M. H., & Cusi, K. J. (2016) · Diabetes Care · doi:10.2337/dc15-1876 · Cited by 151
Andersson, A., Kelly, M., Imajo, K., Nakajima, A., Fallowfield, J. A., Hirschfield, G., Pavlides, M., Sanyal, A. J., Noureddin, M., Banerjee, R., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.09.041 · Cited by 148
Barb, D., Repetto, E., Stokes, M. E., Shankar, S. S., & Cusi, K. J. (2021) · Obesity · doi:10.1002/oby.23263 · Cited by 148
Self-citationGuo, Z., Li, M., Han, B., & Qi, X. (2018) · Digestive and Liver Disease · doi:10.1016/j.dld.2018.08.012 · Cited by 147
Nonalcoholic steatohepatitis clinical research network
(2003) · Hepatology · doi:10.1002/hep.510370203 · Cited by 147
Arab, J. P., Dirchwolf, M., Álvares‐da‐Silva, M. R., Francisco Barrera, M., Benítez, C., Castellanos, M., Castro‐Narro, G., Chávez-Tapia, N. C., Chiodi, D., Cotrim, H. P., et al. (2020) · Annals of Hepatology · doi:10.1016/j.aohep.2020.09.006 · Cited by 146
Kaplan, D. E., Serper, M. A., Mehta, R., Fox, R., John, B., Aytaman, A., Baytarian, M., Hunt, K., Albrecht, J., Njei, B., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.026 · Cited by 145
The Future of Thiazolidinedione Therapy in the Management of Type 2 Diabetes Mellitus
Yau, H., Rivera, K., Lomonaco, R., & Cusi, K. J. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0378-8 · Cited by 143
Schattenberg, J. M., Lazarus, J. V., Newsome, P. N., Serfaty, L., Aghemo, A., Augustín, S., Tsochatzis, E. A., de Lédinghen, V., Bugianesi, E., Romero‐Gómez, M., et al. (2021) · Liver International · doi:10.1111/liv.14825 · Cited by 143
Smits, M. M., Ioannou, G. N., Boyko, E. J., & Utzschneider, K. M. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12106 · Cited by 142
Tamoxifen Inhibits Topoisomerases, Depletes Mitochondrial DNA, and Triggers Steatosis in Mouse Liver
Larosche, I., Lettéron, P., Fromenty, B., Vadrot, N., Abbey‐Toby, A., Feldmann, G., Pessayre, D., & Mansouri, A. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.114546 · Cited by 142
Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Pouwels, P. J. W., Pieters-van den Bos, I. C., Hoekstra, T., Diamant, M., van Raalte, D. H., & Cahen, D. L. (2016) · Diabetologia · doi:10.1007/s00125-016-4100-7 · Cited by 142
Shields, W., Thompson, K., Grice, G. A., Harrison, S. A., & Coyle, W. J. (2009) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x09105462 · Cited by 141
Alexopoulos, A., Crowley, M. J., Wang, Y., Moylan, C. A., Guy, C. D., Henao, R., Piercy, D. L., Seymour, K. A., Sudan, R., Portenier, D. D., et al. (2021) · Hepatology · doi:10.1002/hep.31806 · Cited by 141
Self-citationAjmera, V. H., Kim, B. K., Yang, K. Y., Majzoub, A. M., Nayfeh, T., Tamaki, N., Izumi, N., Nakajima, A., Idılman, R., Gümüşsoy, M., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.06.073 · Cited by 141
Self-citationNoureddin, M., Jones, C., Alkhouri, N., Gomez, E. V., Dieterich, D. T., Rinella, M. E., Therapondos, G., Girgrah, N., Mantry, P. S., Sussman, N. L., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.07.050 · Cited by 140
Self-citationKalinowski, P., Paluszkiewicz, R., Wróblewski, T., Remiszewski, P., Grodzicki, M., Bartoszewicz, Z., & Krawczyk, M. (2016) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2016.08.025 · Cited by 136
Nishino, M., Hayakawa, K., Nakamura, Y., Morimoto, T., & Mukaihara, S. (2003) · American Journal of Roentgenology · doi:10.2214/ajr.180.1.1800129 · Cited by 134
Energy compensation and adiposity in humans
Careau, V., Halsey, L. G., Pontzer, H., Ainslie, P. N., Andersen, L. F., Anderson, L. J., Arab, L., Baddou, I., Bedu-Addo, K., Blaak, E. E., et al. (2021) · Current Biology · doi:10.1016/j.cub.2021.08.016 · Cited by 133
Liver Pathology in Morbidly Obese Patients Undergoing Roux-en-Y Gastric Bypass Surgery
Gholam, P. M., Kotler, D. P., & Flancbaum, L. (2002) · Obesity Surgery · doi:10.1381/096089202321144577 · Cited by 132
Wu, J., Yao, X.-Y., Shi, R.-X., Liu, S.-F., & Wang, X.-Y. (2018) · Reproductive Health · doi:10.1186/s12978-018-0519-2 · Cited by 130
Liu, F., Goh, G. B., TINIAKOS, D. G., Wee, A., Leow, W. Q., Zhao, J., Rao, H., Wang, X., Wang, Q., Wan, W., et al. (2019) · Hepatology · doi:10.1002/hep.30986 · Cited by 130
Tamaki, N., Munaganuru, N., Jung, J., Yonan, A. Q., Loomba, R. R., Bettencourt, R., Ajmera, V., Valasek, M. A., Behling, C., Sirlin, C. B., et al. (2022) · Gut · doi:10.1136/gutjnl-2021-324264 · Cited by 130
Self-citationGenetic Pathways in Nonalcoholic Fatty Liver Disease: Insights From Systems Biology
Sookoian, S. C., Pirola, C. J., Valenti, L. V. C., & Davidson, N. O. (2020) · Hepatology · doi:10.1002/hep.31229 · Cited by 130
Visceral Obesity Predicts Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
Yu, S. J., Kim, W. K., Kim, D., Yoon, J., Lee, K., Kim, J. H., Cho, E. J., Lee, J., Kim, H. Y., Kim, Y. J., et al. (2015) · Medicine · doi:10.1097/md.0000000000002159 · Cited by 128
Germline Mutations in CIDEB and Protection against Liver Disease
Verweij, N., Haas, M. E., Nielsen, J. B., Sosina, O. A., Kim, M., Akbari, P., De, T., Hindy, G., Bovijn, J., Persaud, T., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2117872 · Cited by 127
Navarro, V. J., Belle, S. H., D’Amato, M., Adfhal, N., Brunt, E. M., Fried, M. W., Reddy, K. R., Wahed, A. S., Harrison, S., & on behalf of the Silymarin in NASH and C Hepatitis (SyNCH) Study Group (2019) · PLoS ONE · doi:10.1371/journal.pone.0221683 · Cited by 125
Mantovani, A., Rigamonti, A., Bonapace, S., Bolzan, B., Pernigo, M., Morani, G., Franceschini, L., Bergamini, C., Bertolini, L., Valbusa, F., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0091 · Cited by 124
Factors associated with histologic response in adult patients with nonalcoholic steatohepatitis
Loomba, R., Sanyal, A. J., Kowdley, K. V., Terrault, N., Chalasani, N. P., Abdelmalek, M. F., McCullough, A. J., Shringarpure, R., Ferguson, B., Lee, L., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.09.021 · Cited by 124
Self-citationPioglitazone and Risk for Bone Fracture: Safety Data from a Randomized Clinical Trial
Viscoli, C. M., Inzucchi, S. E., Young, L. H., Insogna, K. L., Conwit, R., Furie, K. L., Gorman, M., Kelly, M. A., Lovejoy, A. M., Kernan, W. N., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3237 · Cited by 124
Ichikawa, T., Nakao, K., Hamasaki, K., FURUKAWA, R., Tsuruta, S., Ueda, Y., Taura, N., Shibata, H., Fujimoto, M., Toriyama, K., et al. (2007) · Hepatology International · doi:10.1007/s12072-007-9007-4 · Cited by 123
Tamoxifen-induced fatty liver in patients with breast cancer
Ogawa, Y., Murata, Y., Nishioka, A., Inomata, T., & Yōshida, S. (1998) · The Lancet · doi:10.1016/s0140-6736(05)78493-2 · Cited by 123
Double diabetes: a distinct high-risk group?
Kietsiriroje, N., Pearson, S., Campbell, M., Ariëns, R. A. S., & Ajjan, R. A. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13848 · Cited by 123
Kawaguchi, T., Charlton, M., Kawaguchi, A., Yamamura, S., Nakano, D., Tsutsumi, T., Zafer, M., & Torimura, T. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1723751 · Cited by 122
Neuschwander‐Tetri, B. A. (2008) · Archives of Internal Medicine · doi:10.1001/archinternmed.2007.131 · Cited by 120
Self-citationMorris‐Stiff, G. J., Tan, Y.-M., & Vauthey, J. (2007) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2007.07.007 · Cited by 118
Gidener, T., Ahmed, O. T., Larson, J. J., Mara, K. C., Therneau, T. M., Venkatesh, S. K., Ehman, R. L., Yin, M., & Allen, A. M. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.09.044 · Cited by 117
Global epidemiology of lean non‐alcoholic fatty liver disease: A systematic review and meta‐analysis
Lu, F., Zheng, K. I., Rios, R. S., Targher, G., Byrne, C. D., & Zheng, M. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15156 · Cited by 116
Sanders, F. W. B., Acharjee, A., Walker, C., Marney, L., Roberts, L. D., Imamura, F., Jenkins, B., Case, J., Ray, S., Virtue, S., et al. (2018) · Genome Biology · doi:10.1186/s13059-018-1439-8 · Cited by 114
Mechanistic review of drug-induced steatohepatitis
Schumacher, J. D., & Guo, G. L. (2015) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2015.08.022 · Cited by 113
Fat or Fit: What Is More Important?
Hainer, V., Toplak, H., & Štich, V. (2009) · Diabetes Care · doi:10.2337/dc09-s346 · Cited by 112
Coronary artery disease in decompensated patients undergoing liver transplantation evaluation
Patel, S. S., Nabi, E. H., Guzmán, L., Abbate, A., Bhati, C. S., Stravitz, R. T., Reichman, T., Matherly, S. C., Driscoll, C. J., Lee, H., et al. (2018) · Liver Transplantation · doi:10.1002/lt.25012 · Cited by 111
Self-citationLoomba, R. S., Bettencourt, R., & Barrett-Connor, E. L. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04141.x · Cited by 110
Self-citationMishra, P., Nugent, C., Afendy, A., Bai, C., Bhatia, P., Afendy, M., Fang, Y. H., Elariny, H. A., Goodman, Z. D., & Younossi, Z. M. (2008) · Liver International · doi:10.1111/j.1478-3231.2008.01822.x · Cited by 110
Abdelbasset, W. K., Tantawy, S. A., Kamel, D. M., Alqahtani, B. A., & Soliman, G. S. (2019) · Medicine · doi:10.1097/md.0000000000014918 · Cited by 109
Review article: impact of exercise on physical frailty in patients with chronic liver disease
Williams, F. R., Berzigotti, A., Lord, J. M., Lai, J. C., & Armstrong, M. J. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15491 · Cited by 109
Zhou, X., Yu, J., Li, L., Gloy, V., Nordmann, A. J., Tiboni, M. E., Li, Y., & Sun, X. (2016) · Obesity Surgery · doi:10.1007/s11695-016-2144-x · Cited by 108
Chen, Y.-P., Lu, F.-B., Hu, Y.-B., Xu, L.-M., Zheng, M.-H., & Hu, E.-D. (2019) · Clinical Nutrition · doi:10.1016/j.clnu.2018.11.030 · Cited by 106
Lai, L. L., Yusoff, W. N. I. W., Vethakkan, S. R., Mustapha, N. R. N., Mahadeva, S., & Chan, W. (2018) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14577 · Cited by 106
Lowe, M., Miller‐Kovach, K., & Phelan, S. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801521 · Cited by 105
Distinct Dysregulation of Lipid Metabolism by Unliganded Thyroid Hormone Receptor Isoforms
Araki, O., Ying, H., Zhu, X., Willingham, M. C., & Cheng, S.-Y. (2009) · Molecular Endocrinology · doi:10.1210/me.2008-0311 · Cited by 105
Glucocorticoids inhibit mitochondrial matrix acyl-CoA dehydrogenases and fatty acid beta-oxidation
Letteron, P., Brahimi-Bourouina, N., Robin, M. A., Moreau, A., Feldmann, G., & Pessayre, D. (1997) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1997.272.5.g1141 · Cited by 105
Sookoian, S. C., & Pirola, C. J. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14401 · Cited by 103
Histological Course of Nonalcoholic Fatty Liver Disease in Japanese Patients
Hamaguchi, E., Takamura, T., Sakurai, M., Mizukoshi, E., Zen, Y., Takeshita, Y., Kurita, S., Arai, K., Yamashita, T., Sasaki, M., et al. (2009) · Diabetes Care · doi:10.2337/dc09-0148 · Cited by 102
Barb, D., Bril, F., Kalavalapalli, S., & Cusi, K. J. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02414 · Cited by 100
Self-citationPolycystic ovary syndrome (PCOS) is associated with NASH severity and advanced fibrosis
Sarkar, M., Terrault, N., Chan, W., Cedars, M. I., Huddleston, H. G., Duwaerts, C. C., Balitzer, D., & Gill, R. M. (2020) · Liver International · doi:10.1111/liv.14279 · Cited by 99
The association of nonalcoholic steatohepatitis and tamoxifen in patients with breast cancer
Saphner, T., Triest‐Robertson, S., Li, H., & Holzman, P. C. (2009) · Cancer · doi:10.1002/cncr.24374 · Cited by 98
Bril, F., Portillo Sanchez, P., Lomonaco, R., Orsak, B., Hecht, J., Tio, F., & Cusi, K. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00867 · Cited by 97
Ramezani‐Binabaj, M., Motalebi, M., Karimi‐Sari, H., Zavareh, M. S. R., & Alavian, S. M. (2014) · Hepatitis Monthly · doi:10.5812/hepatmon.23235 · Cited by 96
Practice patterns in NAFLD and NASH: real life differs from published guidelines
Rinella, M. E., Lominadze, Z., Loomba, R. S., Charlton, M., Neuschwander‐Tetri, B. A., Caldwell, S. H., Kowdley, K. V., & Harrison, S. A. (2015) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x15611581 · Cited by 96
Self-citationHarnessing Muscle–Liver Crosstalk to Treat Nonalcoholic Steatohepatitis
Chakravarthy, M. V., Siddiqui, M. S., Forsgren, M. F., & Sanyal, A. J. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.592373 · Cited by 96
Self-citationBertot, L. C., Jeffrey, G. P., Wallace, M., MacQuillan, G. C., Garas, G., Ching, H. L., & Adams, L. A. (2017) · Hepatology Communications · doi:10.1002/hep4.1018 · Cited by 95
Chemotherapy-associated steatohepatitis
Meunier, L., & Larrey, D. G. (2020) · Annals of Hepatology · doi:10.1016/j.aohep.2019.11.012 · Cited by 94
Statins Are Underutilized in Patients with Nonalcoholic Fatty Liver Disease and Dyslipidemia
Blais, P., Lin, M. F., Kramer, J. R., El‐Serag, H. B., & Kanwal, F. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-4000-6 · Cited by 93
Yilmaz, Y. N., Kurt, R., Yönal, O., Polat, N., Çelikel, Ç., Gürdal, A., Oflaz, H., Ozdogan, O. C., İmeryüz, N., Kalaycı, C., et al. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.01.049 · Cited by 92
Majzoub, A. M., Nayfeh, T., Barnard, A., Munaganuru, N., Dave, S., Singh, S., Murad, M. H., & Loomba, R. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16583 · Cited by 92
Self-citationMorrison, A. E., Zaccardi, F., Khunti, K., & Davies, M. J. (2019) · Liver International · doi:10.1111/liv.13994 · Cited by 92
Younossi, Z. M., Corey, K. E., Alkhouri, N., Noureddin, M., Jacobson, I. M., Lam, B. P., Clement, S. C., Basu, R., Gordon, S. C., Ravendhra, N., et al. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15830 · Cited by 92
Self-citationMBOAT7 down-regulation by genetic and environmental factors predisposes to MAFLD
Meroni, M., Longo, M., Fracanzani, A. L., & Dongiovanni, P. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102866 · Cited by 92
Dietary Supplement Use and Prostate Cancer Risk in the Carotene and Retinol Efficacy Trial
Neuhouser, M. L., Barnett, M. J., Kristal, A. R., Ambrosone, C. B., King, I. B., Thornquist, M. D., & Goodman, G. G. (2009) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-09-0013 · Cited by 91
Staufer, K., Halilbasic, E., Spindelboeck, W., Eilenberg, M., Prager, G., Stadlbauer, V., Posch, A., Munda, P., Marculescu, R., Obermayer-Pietsch, B. M., et al. (2019) · United European Gastroenterology Journal · doi:10.1177/2050640619865133 · Cited by 89
Acute severe steatohepatitis related to prednisolone therapy
Dourakis, S. P., Sevastianos, V., & Patsiaoura, K. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05644.x · Cited by 88
Mueller, K. M., Themanns, M., Friedbichler, K., Kornfeld, J., Esterbauer, H., Tuckermann, J. P., & Moriggl, R. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.03.026 · Cited by 88
Stanley, T. L., Fourman, L. T., Feldpausch, M. N., Purdy, J., Zheng, I., Pan, C. S., Aepfelbacher, J., Buckless, C. G., Tsao, A., Kellogg, A., et al. (2019) · The Lancet HIV · doi:10.1016/s2352-3018(19)30338-8 · Cited by 88
Self-citationAbdelmalek, M. F., Liu, C., Shuster, J. J., Nelson, D. R., & Asal, N. R. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.06.001 · Cited by 87
Self-citationAssociation Between Puberty and Features of Nonalcoholic Fatty Liver Disease
Suzuki, A., Abdelmalek, M. F., Schwimmer, J. B., Lavine, J. E., Scheimann, A. O., Ünalp–Arida, A., Yates, K. P., Sanyal, A. J., Guy, C. D., & Diehl, A. M. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.01.020 · Cited by 87
Self-citationSumida, Y., Yonei, Y., Tanaka, S., Mori, K., Kanemasa, K., Imai, S., Taketani, H., Hara, T., Seko, Y., Ishiba, H., et al. (2014) · Hepatology Research · doi:10.1111/hepr.12408 · Cited by 87
Bohinc, B. N., Michelotti, G. A., Xie, G., Pang, H., Suzuki, A., Guy, C. D., Piercy, D. L., Krüger, L., Swiderska‐Syn, M., Machado, M. V., et al. (2014) · Endocrinology · doi:10.1210/en.2014-1302 · Cited by 86
Self-citationBlomdahl, J., Nasr, P., Ekstedt, M., & Kechagias, S. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154439 · Cited by 86
Jirapinyo, P., McCarty, T. R., Dolan, R. D., Shah, R., & Thompson, C. C. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.03.017 · Cited by 86
Emerging role of genomic analysis in clinical evaluation of lean individuals with NAFLD
Vilarinho, S., Ajmera, V., Zheng, M., & Loomba, R. (2021) · Hepatology · doi:10.1002/hep.32047 · Cited by 85
Self-citationStockman, J. A. (2012) · Yearbook of Pediatrics · doi:10.1016/j.yped.2011.06.073 · Cited by 84
Haider, A., Gooren, L. J. G., Padungtod, P., & Saad, F. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1202774 · Cited by 83
Radun, R., & Trauner, M. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1731707 · Cited by 83
Depboylu, G. Y., Akbulut, G., Baran, M., & Yılmaz, C. (2021) · Pediatric Obesity · doi:10.1111/ijpo.12872 · Cited by 83
Jinjuvadia, R., Antaki, F., Lohia, P., & Liangpunsakul, S. (2016) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000666 · Cited by 82
Jaruvongvanich, V., Sanguankeo, A., & Upala, S. (2017) · European Thyroid Journal · doi:10.1159/000454920 · Cited by 82
Menopause and Non-Alcoholic Fatty Liver Disease: A Review Focusing on Therapeutic Perspectives
Venetsanaki, V., & Pοlyzos, S. A. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666180711121949 · Cited by 81
Tamoxifen-Induced Steatohepatitis
Pratt, D. S., Knox, T. A., & Erban, J. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-3-199508010-00018 · Cited by 78
Murata, Y., Ogawa, Y., Saibara, T., Nishioka, A., Fujiwara, Y., Fukumoto, M., Inomata, T., Enzan, H., Onishi, S., & Yōshida, S. (2000) · Oncology Reports · doi:10.3892/or.7.6.1299 · Cited by 77
Kim, N. H., Kim, J. H., Kim, Y. J., Yoo, H. J., Kim, H. Y., Seo, J. A., Kim, N. H., Choi, K. M., Baik, S. H., Choi, D. S., et al. (2014) · Liver International · doi:10.1111/liv.12454 · Cited by 77
Day, J. W., Patel, P. J., Parkes, J., & Rosenberg, W. M. (2018) · The Journal of Applied Laboratory Medicine · doi:10.1373/jalm.2018.027359 · Cited by 77
Cheung, A. C., Neuschwander‐Tetri, B. A., Kleiner, D. E., Schabel, E., Rinella, M. E., Harrison, S. A., Ratziu, V., Sanyal, A. J., Loomba, R. S., Megnien, S. J., et al. (2019) · Hepatology · doi:10.1002/hep.30672 · Cited by 77
Self-citationEguchi, Y., Mizuta, T., Sumida, Y., Ishibashi, E., Kitajima, Y., Isoda, H., Horie, H., Tashiro, T., Iwamoto, E., Takahashi, K., et al. (2010) · Journal of Gastroenterology · doi:10.1007/s00535-010-0340-3 · Cited by 76
George, E. S., Reddy, A., Nicoll, A. J., Ryan, M. C., Itsiopoulos, C., Abbott, G., Johnson, N. A., Sood, S., Roberts, S. K., & Tierney, A. C. (2022) · Liver International · doi:10.1111/liv.15264 · Cited by 76
Kouvari, M., Boutari, C., Chrysohoou, C. A., Fragkopoulou, E., Antonopoulou, S., Tousoulis, D., Pitsavos, C. S., Panagiotakos, D. B., & Mantzoros, C. S. (2020) · Clinical Nutrition · doi:10.1016/j.clnu.2020.10.058 · Cited by 76
Malespin, M. H., Barritt, A. S., Watkins, S. E., Schoen, C., Tincopa, M. A., Corbin, K. D., Mospan, A. R., Munoz, B., Trinh, H. N., Weiss, L. M., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.01.023 · Cited by 75
Self-citationChang, Y., Ryu, S., Kim, Y., Cho, Y. K., Sung, E., Kim, H., Ahn, J., Jung, H. S., Yun, K. E., Kim, S., et al. (2019) · Hepatology · doi:10.1002/hep.30867 · Cited by 74
Franco, I., Bianco, A., Mirizzi, A., Campanella, A., Bonfiglio, C., Sorino, P., Notarnicola, M., Tutino, V., Cozzolongo, R., Giannuzzi, V., et al. (2020) · Nutrients · doi:10.3390/nu13010066 · Cited by 73
Gómez, E. V., Pirola, C. J., Sookoian, S. C., Wilson, L., Belt, P. H., Liang, T., Liu, W., & Chalasani, N. (2020) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001072 · Cited by 73
Is there an ‘ideal’ diet for patients with NAFLD?
Pugliese, N., Torres, M. C. P., Petta, S., Valenti, L. V. C., Giannini, E. G., & Aghemo, A. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13659 · Cited by 73
Alam, S., Ghosh, J., Mustafa, G., Kamal, M. A., & Ahmad, N. (2018) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s158053 · Cited by 72
The Hierarchical Model of NAFLD: Prognostic Significance of Histologic Features in NASH
Loomba, R. S., & Chalasani, N. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.06.016 · Cited by 71
Self-citationMantovani, A., Turino, T., Lando, M. G., Gjini, K., Byrne, C. D., Zusi, C., Ravaioli, F., Colecchia, A., Maffeis, C., Salvagno, G. L., et al. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.11.004 · Cited by 71
Low Testosterone Is Associated With Nonalcoholic Steatohepatitis and Fibrosis Severity in Men
Sarkar, M. A., Yates, K. P., Suzuki, A., Lavine, J. E., Gill, R. M., Ziegler, T. E., Terrault, N. A., & Dhindsa, S. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.11.053 · Cited by 71
Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes
Cusi, K. J. (2020) · Diabetes Care · doi:10.2337/dci19-0064 · Cited by 71
Stewart, K. E., Haller, D. L., Sargeant, C., Levenson, J. L., Puri, P., & Sanyal, A. J. (2014) · Liver International · doi:10.1111/liv.12483 · Cited by 69
Cited by
Sorted by citations
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476
“Moreover, this nomenclature process, in line with published guidance [21,28,29], is not advocating for the routine use of tests to con fi rm hepatic steatosis although, in reality, most, if not all, patients will usually have imaging at some point.”
Self-citationA multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.06.003 · Cited by 3,100
Self-citationTacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association
Ndumele, C. E., Rangaswami, J., Chow, S. L., Neeland, I. J., Tuttle, K. R., Khan, S. S., Coresh, J., Mathew, R. O., Baker-Smith, C. M., Carnethon, M. R., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001184 · Cited by 2,208
A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis
Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309000 · Cited by 2,084
Self-citation
Metadata
- Authors
- Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R.
- Affiliations
- University of Chicago (US)
- Saint Louis University School of Medicine, Saint Louis, Missouri, USA
- Virginia Commonwealth University (US)
- Mayo Clinic (US)
- University of Virginia (US)
- University of Florida Health (US)
- National Institutes of Health (US)
- University of California San Diego (US)
- Corresponding author
- Rinella, Mary E.
- ORCID
- Venue
- Hepatology
- Published
- 2023-03-17
- Volume
- 77
- Issue
- 5
- Pages
- 1797-1835
- ISSN
- 0270-9139 (ISSN-L)
- PMC
- PMC10735173
- OpenAlex
- W4318923555
- Cited by
- 2,667
- References
- 502
- Citations by year
- 2026: 849 · 2025: 845 · 2024: 691 · 2023: 281
- FWCI
- 532.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- American Association for the Study of Liver Diseases
- NGM Biopharmaceuticals
- Novo Nordisk
- National Institutes of Health
- Allergan
- National Cancer Institute (ZICBC010685)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, non-invasive risk stratification, non-invasive tests, fibrosis staging, liver cirrhosis
- MeSH terms
- Humans, Liver, Liver Cirrhosis, Disease Progression, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
